🔎 Trials Near Me

Akèy › Kansè Poumon ki pa ti selil › Distrik Columbia

Etid klinik pou Kansè Poumon ki pa ti selil nan Distrik Columbia

38 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan Distrik Columbia.

Vil nan Distrik Columbia

Tèks ofisyèl etid la (Anglè)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
  • MedStar Georgetown University Hospital, Washington D.C.
  • MedStar Washington Hospital Center, Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 5, 2026 · NCT04267848

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06472245

A Study of PHN-012 in Patients With Advanced Solid Tumors

  • PHN-012-001 Site, Washington D.C.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07127874

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  • Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05498428

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • MedStar Georgetown University Hospital, Washington D.C.
  • Washington DC VA Medical Center, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Georgetown University, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07154290

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  • Washington DC Veterans Affairs Medical Center, Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • MedStar Georgetown University Hospital, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT03191149

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • Sibley Memorial Hospital, Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06890598

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH), Washington D.C.
  • MEDSTAR Washington Hospital Center (MedStar Health Research Institute), Washington D.C.
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06712316

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Georgetown University Medical Center, Washington D.C.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT05983432

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  • George Washington University Cancer Center, Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07195695

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

  • Georgetown University Lombardi Cancer Center, Washington D.C.
  • Sibley Memorial Hospital, Washington D.C.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • Local Institution - 007-5476, Washington D.C.
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

  • MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT04302025

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Sibley Memorial Hospital, Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

  • Washington Hospital Center ( Site 0037), Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06422143

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  • MedStar Georgetown University Hospital, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07288177

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

  • Sibley Memorial Hospital, Washington D.C.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT06586515

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

  • Sibley Memorial Hospital, Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT06500481

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  • Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07111520

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

  • Georgetown University Medical Center, Washington D.C.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06706076

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

  • Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT06449313

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  • Georgetown University, Washington D.C.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 21, 2026 · NCT05098132

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

  • Georgetown University Medical Center, Washington D.C.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06162221

Gilteritinib for the Treatment of ALK NSCLC

  • Georgetown University, Washington D.C.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 26, 2026 · NCT06225427

Study of XB010 in Subjects With Solid Tumors

  • Georgetown University Medical Center, Washington D.C.
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 22, 2026 · NCT06545331

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

  • Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 3, 2026 · NCT05642572

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

  • Georgetown University Medical Cener (GUMC), Washington D.C.
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou May 19, 2026 · NCT07154706

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

  • Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
Ap rekriteFaz 2
18 Minutes · Tout sèks · Mizajou May 5, 2026 · NCT06031688

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

  • Sibley Memorial Hospital, Washington D.C.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT06810544

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
  • Medstar Washington Hospital Center, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 16, 2026 · NCT04499053

Repositioning Immunotherapy in VetArans With Lung Cancer

  • VA Central Office, Washington, DC, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 2, 2026 · NCT06275360

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  • The George Washington University Cancer Center (site 212), Washington D.C.
Ap rekriteFaz 1/2
Laj 18 a 80 · Tout sèks · Mizajou Dec 11, 2025 · NCT03556228

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2025 · NCT06669117

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.